Treatment of Chronic Hepatitis B: Highlights From the 41st Annual Meeting of the European Associatio...
Download
1 / 7

Emmet B. Keeffe, MD, MACP Professor of Medicine Chief of Hepatology - PowerPoint PPT Presentation


  • 126 Views
  • Uploaded on

Treatment of Chronic Hepatitis B: Highlights From the 41st Annual Meeting of the European Association for the Study of the Liver. Emmet B. Keeffe, MD, MACP Professor of Medicine Chief of Hepatology Co-Director, Liver Transplant Program Stanford University Medical Center.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Emmet B. Keeffe, MD, MACP Professor of Medicine Chief of Hepatology' - livi


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

Treatment of Chronic Hepatitis B: Highlights From the 41st Annual Meeting of the European Association for the Study of the Liver

Emmet B. Keeffe, MD, MACP

Professor of Medicine

Chief of Hepatology

Co-Director, Liver Transplant Program

Stanford University Medical Center

Supported by an independent educational grant from


Adefovir dipivoxil long term therapy
Adefovir Dipivoxil Annual Meeting of the European Association for the Study of the LiverLong-term Therapy

  • Safety and efficacy over 4-5 years demonstrated[1,2]

    • 55% in 4-yr cohort and 71% in 5-yr cohort had >/= 1-point improvement in Ishak fibrosis score

    • Majority of patients normalized ALT and suppressed serum HBV DNA < 1000 copies/mL

    • Adverse events uncommon: 3% increased serum creatinine >/= 0.5 mg/dL

    • Adefovir resistance mutations: 0%, 3%, 11%, 18%, and 29% detected at 1, 2, 3, 4, and 5 years, respectively

  • Durability of HBeAg seroconversion = 91%[3]

  • Addition of adefovir to lamivudine before and after liver transplantation prevents graft reinfection[4]

1. Hadziyannis S, et al. J Hepatol.2006;44(Suppl 2):S283-S290. Abstract 494.

2. Borroto-Esoda K, et al. J Hepatol. 2006;44(Suppl 2):S179-S180.Abstract 483.

3. Chang TT, et al. J Hepatol. 2006;44(Suppl 2):S187.Abstract 503.

4. Schiff E, et al. J Hepatol. 2006;44(Suppl 2):S3.Abstract #2.


Adefovir for hbeag negative chronic hepatitis b reduction of fibrosis score 1 point
Adefovir for HBeAg-Negative Chronic Hepatitis B Annual Meeting of the European Association for the Study of the LiverReduction of Fibrosis Score >/= 1 Point

Hadziyannis S, et al. J Hepatol. 2006;44(Suppl 2):S283-S290. Abstract 494.


Entecavir 96 weeks of therapy
Entecavir Annual Meeting of the European Association for the Study of the Liver96 Weeks of Therapy

  • Among patients with only a virologic response after 48 weeks of therapy treated for a second year, 96% treated with entecavir vs 64% treated with lamivudine had an HBV DNA level < 300 copies/mL[1]

  • Cumulative virologic response for all patients through Week 96 (HBV DNA < 300 copies/mL) was 94% for entecavir and 77% for lamivudine[1]

  • No evidence of entecavir resistance found in nucleoside-naive patients lacking lamivudine resistance at study entry and treated for 96 weeks[2]

1. Shouval D, et al. J Hepatol. 2006;44(Suppl 2):S21-S22.Abstract 45.

2. Colonno R, et al. J Hepatol. 2006;44(Suppl 2):S182. Abstract 490.


Peginterferon alfa 2a effect on fibrosis progression
Peginterferon alfa-2a Annual Meeting of the European Association for the Study of the LiverEffect on Fibrosis Progression

  • Paired pretreatment and 24-week posttreatment biopsies analyzed

  • In HBeAg-positive patients, 33% had improved fibrosis and 33% had no change

  • In HBeAg-negative patients, 39% had improved fibrosis and 37% had no change

  • Rates of improved or stabilized fibrosis were significantly higher in patients with sustained serologic or virologic response at Week 72

Cooksley G, et al. J Hepatol. 2006;44(Suppl 2):S182-S183. Abstract 491.


Telbivudine 52 and 76 weeks of therapy
Telbivudine Annual Meeting of the European Association for the Study of the Liver52 and 76 Weeks of Therapy

*HBV DNA never < 5 log10 copies/mL; †P < .01

Ldt = telbivudine; Lam = lamivudine

Gane E, et al. J Hepatol. 2006;44(Suppl 2):S183-S184. Abstract 493.


Drugs for chronic hepatitis b licensed and under development
Drugs for Chronic Hepatitis B Annual Meeting of the European Association for the Study of the LiverLicensed and Under Development

www.hivandhepatitis.com


ad